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ORIGINAL RESEARCH

Risk Stratiﬁcation for Bleeding Complications in Patients With Venous
Thromboembolism: Application of the HAS-BLED Bleeding Score
During the First 6 Months of Anticoagulant Treatment
Joshua D. Brown, PharmD, PhD; Amie J. Goodin, PhD, MPP; Gregory Y. H. Lip, MD, FRCP, DFM, FACC, FESC; Val R. Adams, PharmD, BCOP

Background-—The Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR),
Elderly, Drugs or alcohol use (HAS-BLED) score has strong predictive validity for major bleeding complications, but limited
validation has been conducted in venous thromboembolism (VTE). This study evaluates the HAS-BLED score in a large cohort of
VTE patients.
Methods and Results-—A retrospective cohort of adults ≥18 years with primary diagnosis of VTE between January 1, 2010 and
November 31, 2013 were identiﬁed in an insurance claims database. Patients were tracked until death, any bleed event, or end of
study period. HAS-BLED score and components were evaluated via proportional hazard models. Cumulative incidence functions
were reported at 30, 60, 90, and 180 days. N=132 280 patients with a VTE were identiﬁed, with 73.8% having HAS-BLED scores of
0 to 2, 3.6% score ≥4, and 4789 bleeding events (3.6% all patients). A 1-point HAS-BLED score increase was associated with 20% to
30% bleeding rate increase overall, but in a cancer cohort only the increase from 3- to 4-points was signiﬁcant for all bleeds
(csHR=1.41, 95% CI: 1.17–1.69; sdHR=1.40, 95% CI: 1.17–1.69) and major bleeds (csHR=1.66, 95% CI: 1.26–2.20; sdHR=1.66,
95% CI: 1.25–2.19). Adding cancer to the model as an independent covariate provided the strongest association among all
covariates, with csHR=2.25 (95% CI: 1.98–2.56) and sdHR=2.11 (95% CI: 1.85–2.41) in the model for major bleeds.
Conclusions-—The HAS-BLED score has good predictive validity for bleeding risks in patients with VTE. The addition of cancer as an
independent bleeding risk factor merits consideration, possibly as part of the “B” criterion (“bleeding tendency or predisposition”).
( J Am Heart Assoc. 2018;7:e007901. DOI: 10.1161/JAHA.117.007901.)
Downloaded from http://ahajournals.org by on December 6, 2018
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V

enous thromboembolism (VTE), including both deep vein
thrombosis and pulmonary embolism affects around 1 to
2 adults per 1000 every year.1 The most recent American
College of Chest Physicians (ACCP) guidelines recommend
treatment with non-vitamin K antagonist oral anticoagulants
over vitamin K antagonists (eg, warfarin) in patients without
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cancer for at least 3 months.2 In patients with cancer, lowmolecular weight heparins (LMWH) are recommended over
other treatments. The goal of anticoagulation is to treat the
current VTE and to prevent recurrent VTE. However, anticoagulation also imposes an increased risk for bleeding events
and this risk must be assessed to determine appropriateness
of a given treatment plan for each patient.
In an analogous treatment paradigm, individuals with atrial
ﬁbrillation (AF) often receive long-term anticoagulation for
prevention of cerebrovascular events. In the AF population,
risk scores are now commonly used as clinical decision
support tools to initiate anticoagulation based on stroke risk
(eg, CHADSs and CHA2DS2-VASc).3 More recently, bleeding
risk scores have been developed to go hand-in-hand with
stroke risk scores to determine the potential net clinical
beneﬁt of anticoagulation and to guide patient follow-up
throughout therapy.3
The Hypertension, Abnormal renal/liver function, Stroke,
Bleeding, Labile International Normalized Ratio (INR), Elderly,
Drugs or alcohol use (HAS-BLED) score is one such score and
Journal of the American Heart Association
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What Is New?
• The HAS-BLED score has been widely used for risk
stratiﬁcation in patients with atrial ﬁbrillation receiving
anticoagulation.
• This study shows that HAS-BLED has high predictive validity
for bleeding events in venous thromboembolism (VTE)
patients receiving anticoagulation.
• Further, we show that cancer is a strong independent risk
factor for bleeding in this population and should be included
in the risk score.

What Are the Clinical Implications?
• HAS-BLED can be used in patients with VTE to predict the
risk of a bleeding event while being anticoagulated.
• Bleed risk stratiﬁcation scores should not be used to
withhold treatment.
• Rather, risk scores can be used to identify patients for
monitoring or modiﬁed therapeutic approaches as well as
identiﬁcation of some modiﬁable risk factors (eg, blood
pressure, medication use).

Downloaded from http://ahajournals.org by on December 6, 2018

has been shown to have strong predictive validity for major
bleeding complications.4 HAS-BLED has been validated across
several AF cohorts4,5 and has recently been applied to
patients with VTE to determine its ability to identify those at
the highest risk.6 These prior studies of VTE cohorts have
been limited in size and number of events, and have thus been
unable to establish a clear ability of the HAS-BLED score to
assess bleeding risk in a VTE population.
This study’s primary objective was to evaluate the HASBLED score in a large cohort of VTE patients receiving
outpatient anticoagulation treatment. Second, the HAS-BLED
score was evaluated in a subgroup of VTE patients with
cancer. The latter objective fulﬁlls a crucial gap in the
literature, given that cancer is one of the strongest risk
factors for VTE and presents a more complicated patient
population in regards to additional risk factors for adverse
bleeding events.

Methods
This retrospective cohort study used the Truven Health
MarketScan Commercial Claims and Medicare Supplemental
Databases from the years 2010–2014. The MarketScan data
include 40 million individuals from >160 large employers
and health plans across the United States. The data represent
an individual’s healthcare utilization including medical claims
with diagnosis and procedure codes for medical encounters
and all prescription medication ﬁlls, as well as in-hospital
DOI: 10.1161/JAHA.117.007901

mortality. These data are de-identiﬁed in compliance with the
Health Insurance Portability and Accountability Act regulations
(HIPAA) and the University of Kentucky Institutional Review
Board approved the use of the database for this study. The data
are licensed and are not available for public dissemination.
Codes for analytic methods are available from the authors on
request for purposes of reproducing the study results.

Cohort Selection
Adults aged ≥18 years diagnosed with a VTE event between
January 1, 2010 and November 31, 2013 were identiﬁed. The
date of the ﬁrst qualifying diagnosis of VTE was deﬁned as the
index date, requiring that the diagnosis was in the primary
position on an inpatient hospital record. VTE was identiﬁed by
International Classiﬁcation of Disease, 9th revision (ICD-9)
codes based on previously validated coding algorithms.7
Patients were further required to have at least 12 months of
pre-index and a 1-month minimum of post-index continuous
enrollment with medical and outpatient pharmacy information
included in the database. Patients were also required to be
treatment-na€ıve (ie, no anticoagulant therapy during the
baseline period), to present an anticoagulant treatment na€ıve
cohort.

Cohort Characteristics
The cohort was described by age (18–64, 65–74, ≥75 years)
and sex. All categories for the HAS-BLED score were identiﬁed
by ICD-9 codes including: hypertension, liver disease, history
of stroke, history of bleeding,8 alcohol abuse, and drug
abuse.9 NSAIDs or antiplatelet medications were identiﬁed
from pharmacy records. The “labile INR” criterion of HASBLED was not assessed given that the cohort was required to
be anticoagulant treatment-na€ıve and no such records would
exist.
Patients were assigned a total HAS-BLED score of 1-point
each for hypertension, renal disease, liver disease, history of
stroke, history of bleeding, aged >65 years, medication use
predisposing to bleeding (NSAIDs and antiplatelets), and
alcohol and/or drug abuse. Patients with malignant neoplasms and/or metastatic disease during the baseline period
were also identiﬁed using ICD-9 codes 140.x to 209.x.
Anticoagulant treatment was identiﬁed as the ﬁrst observed
LMWH, non-vitamin K antagonist oral anticoagulant, or
warfarin, allowing for bridge therapy from LMWH to warfarin.

Patient Follow-Up and Outcomes
All bleeding events were tracked during the 180 days
following the initial VTE diagnosis. Patients were followed up
until they experienced a bleeding event, were censored due to
Journal of the American Heart Association
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Statistical Analysis
A time-to-event, survival analytic approach was taken. Given
that there is a high risk of death in the overall cohort, and an
especially elevated risk in the cancer sub-group, it was

deemed necessary to assess outcomes in a competing risks
framework, taking death into account as a competing event to
the primary bleeding outcome.11
The cumulative incidence function (CIF) of all bleeding
events and major bleeding events were modeled using Fine
and Gray’s method for competing risks which reported the
incidence proportion at multiple time periods (30, 60, 90,
180 days).12 CIF plots were stratiﬁed by HAS-BLED scores
and show the incidence of bleeding complications, taking into
account both censoring and competing events during followup. Gray’s statistical tests for the equality of CIF curves
between HAS-BLED stratiﬁcations were conducted.

Table 1. Demographic and Clinical Characteristics of Patients With an Index Venous Thromboembolism
DVT Only

PE With or Without DVT

Overall

N

%

N

%

N

%

60 930

46.1

71 350

53.9

132 280

100

18 to 64

36 731

60.3

47 520

66.6

84 251

63.7

65 to 74

7793

12.8

8978

12.6

16 771

12.7

≥75

16 406

26.9

14 852

20.8

31 258

23.6

Sex (male)

27 734

52.0

32 257

51.5

59 991

45.4

Hypertension

28 682

53.8

30 127

48.1

58 809

44.5

Renal disease

6365

11.9

3770

6.0

10 135

7.7

Liver disease

3826

7.2

3733

6.0

7559

5.7

History of stroke

6943

13.0

5470

8.7

12 413

9.4

History of bleeding

8076

15.2

7405

11.8

15 481

11.7

Medication use (NSAIDs, antiplatelets)

16 443

30.8

19 908

31.8

36 351

27.5

Alcohol or drug use

827

1.6

843

1.4

1670

1.3

Cancer

12 586

23.6

12 329

19.7

24 915

18.8

Metastatic cancer

4197

7.9

4317

6.9

8514

6.4

0

12 564

23.6

18 023

28.8

30 587

23.1

1

16 424

30.8

20 858

33.3

37 282

28.2

2

14 536

27.3

15 282

24.4

29 818

22.5

3

7048

13.2

6389

10.2

13 437

10.2

4

2320

4.4

1786

2.9

4106

3.1

5

397

0.7

251

0.4

648

0.5

6

28

0.1

19

0.0

47

0.0

7

2

0.0





2

0.0

LMWH

5955

11.2

3980

6.4

9935

7.5

NOAC

8465

15.9

12 100

19.3

20 565

15.5

Warfarin

38 899

73.0

46 528

74.3

85 427

64.6

Total
Age, y
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HAS-BLED Score

Anticoagulation

DVT indicates deep vein thrombosis; HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use;
LMWH, low molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; PE, pulmonary embolism.
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dropping out of the database, they died, or until the end of the
study period or follow-up time. Bleeding events were classiﬁed
as “all” if they met the coding algorithm used or “major” if
they occurred during an inpatient stay, were associated with a
critical site, resulted in need for transfusion, or lead to death
while in the hospital.10
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Table 2. Cumulative Incidence Proportion of Bleeding Events at 30, 60, 90, and 180 Days of Follow-Up by HAS-BLED Score
HAS-BLED Score
Time to Bleeding Event

0

1

2

≥4

3

(A) Major bleeds, overall
30 d

0.5% (0.4–0.5%)

0.5% (0.5–0.6%)

0.6% (0.5–0.7%)

0.6% (0.5–0.8%)

1.1% (0.9–1.4%)

60 d

0.6% (0.5–0.7%)

0.7% (0.6–0.8%)

0.8% (0.8–0.9%)

0.8% (0.7–1.0%)

1.7% (1.4–2.0%)

90 d

0.7% (0.6–0.8%)

0.9% (0.8–1.0%)

1.1% (1.0–1.2%)

1.1% (1.0–1.3%)

2.3% (2.0–2.7%)

180 d

0.9% (0.8–1.1%)

1.3% (1.1–1.4%)

1.7% (1.5–1.8%)

2.0% (1.8–2.3%)

3.4% (3.0–3.9%)

30 d

0.4% (0.3–0.5%)

0.5% (0.4–0.5%)

0.5% (0.4–0.6%)

0.6% (0.5–0.8%)

1.0% (0.7–1.3%)

60 d

0.5% (0.4–0.6%)

0.6% (0.5–0.7%)

0.7% (0.6–0.8%)

0.8% (0.6–0.9%)

1.5% (1.2–1.9%)

(B) Major bleeds, no cancer

90 d

0.6% (0.5–0.7%)

0.8% (0.7–0.9%)

0.9% (0.8–1.0%)

1.0% (0.9–1.2%)

2.1% (1.7–2.6%)

180 d

0.7% (0.6–0.8%)

1.0% (0.9–1.2%)

1.3% (1.2–1.5%)

1.8% (1.6–2.1%)

3.1% (2.6–3.7%)

30 d

0.9% (0.7–1.3%)

0.7% (0.6–0.9%)

0.9% (0.7–1.1%)

0.7% (0.5–0.9%)

1.3% (0.9–1.9%)

60 d

1.3% (1.0–1.7%)

1.1% (0.8–1.3%)

1.3% (1.1–1.6%)

1.0% (0.8–1.3%)

1.9% (1.4–2.6%)

90 d

1.7% (1.3–2.1%)

1.3% (1.1–1.6%)

1.7% (1.5–2.0%)

1.3% (1.1–1.7%)

2.7% (2.1–3.4%)

180 d

2.4% (1.9–2.9%)

2.1% (1.8–2.5%)

2.6% (2.2–2.9%)

2.5% (2.1–3.0%)

4.1% (3.3–5.0%)

30 d

1.2% (1.1–1.4%)

1.4% (1.3–1.5%)

1.5% (1.4–1.6%)

1.5% (1.4–1.7%)

2.5% (2.2–2.9%)

60 d

1.6% (1.5–1.8%)

1.9% (1.8–2.1%)

2.1% (1.9–2.2%)

2.2% (2.0–2.4%)

3.7% (3.2–4.2%)

(C) Major bleeds, cancer only

(D) All bleeds, overall

90 d

1.9% (1.8–2.1%)

2.4% (2.2–2.5%)

2.7% (2.6–2.9%)

3.1% (2.8–3.3%)

5.0% (4.5–5.6%)

180 d

2.6% (2.4–2.8%)

3.4% (3.2–3.6%)

4.2% (4.0–4.4%)

5.3% (4.9–5.6%)

8.0% (7.3–8.7%)
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(E) All bleeds, no cancer
30 d

1.0% (0.9–1.2%)

1.3% (1.1–1.4%)

1.3% (1.2–1.5%)

1.6% (1.4–1.8%)

2.3% (1.9–2.8%)

60 d

1.4% (1.2–1.5%)

1.7% (1.6–1.9%)

1.8% (1.7–2.0%)

2.1% (1.9–2.4%)

3.5% (3.0–4.1%)

90 d

1.6% (1.4–1.8%)

2.1% (1.9–2.2%)

2.3% (2.1–2.5%)

2.9% (2.6–3.2%)

4.8% (4.2–5.5%)

180 d

2.1% (2.0–2.3%)

2.9% (2.7–3.1%)

3.6% (3.4–3.9%)

4.8% (4.4–5.2%)

7.6% (6.8–8.5%)

30 d

2.5% (2.0–3.0%)

1.9% (1.6–2.2%)

1.9% (1.6–2.1%)

1.4% (1.2–1.8%)

2.9% (2.2–3.6%)

60 d

3.3% (2.7–3.8%)

2.8% (2.4–3.1%)

2.8% (2.5–3.2%)

2.4% (2.1–2.9%)

4.1% (3.3–4.9%)

(F) All bleeds, cancer only

90 d

4.2% (3.6–4.9%)

3.5% (3.1–3.9%)

3.8% (3.4–4.2%)

3.5% (3.0–4.0%)

5.4% (4.5–6.4%)

180 d

5.9% (5.2–6.7%)

5.4% (4.9–6.0%)

5.8% (5.4–6.3%)

6.3% (5.6–7.0%)

8.6% (7.4–9.9%)

HAS-BLED indicates Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use.

Two proportional hazard regression models speciﬁcations
were used. A cause-speciﬁc model was used which treats the
competing risk as a censoring event. This models the
instantaneous rate of bleeding events among subjects who
are event free at a given time point (no bleeding, no death).
The cause-speciﬁc model is comparable to a typical Cox
proportional hazard model. A sub-distribution model was also
used which accounts directly for death as a competing risk by
retaining those that die within a given time point in the risk
set. Such a model provides an estimate of the instantaneous
rate of bleeding events in those who have not experienced a
DOI: 10.1161/JAHA.117.007901

bleed or have died within the time interval. Including both
models allowed for broader interpretation of results as each
has unique implications and applications.11 Speciﬁcally, using
both approaches allows for an assessment of how the risk of
death interplays with the risk of bleeding and the association
of each with the included covariates.
From each model, cause-speciﬁc (csHR) and sub-distribution (sdHR) hazard ratios and 95% conﬁdence intervals (CI) are
reported for the HAS-BLED score, individual components of
the HAS-BLED score, and for cancer. To better compare HASBLED scores and potential low/high risk cut-offs, hazard
Journal of the American Heart Association
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Results
Over the study period, N=132 280 patients with VTE were
identiﬁed including 60 930 (46.1%) with deep vein thrombosis
and 71 350 (53.9%) with pulmonary embolism (Table 1).
Nearly two-thirds were aged 18 to 64 years (63.7%), and
45.4% were male. The most common HAS-BLED component
was hypertension (44.5%), followed by NSAID or antiplatelet
medication use (27.5%), cancer (18.8%), and a history of
bleeding (11.7%). The large majority of patients had HAS-BLED
scores of 0 to 2, 10.2% had a score of 3, and 3.6% had a score
≥4. The majority of patients received warfarin (64.6%), 15.5%
received non-vitamin K antagonist oral anticoagulants, and
7.5% received LMWH. Treatment did not differ based on the
HAS-BLED score in the overall cohort but cancer patients

were more likely to receive LMWH than non-cancer patients,
which is consistent with US treatment guidelines.2,13
There were a total of 4789 (3.6% of all patients) bleeding
events of which, 1847 (38.6%) were classiﬁed as major
bleeds. Median time to bleed was 50 days (mean 62 days) for
all bleeds as well as major bleeds. An additional 2739 patients
(2.1% of all patients) died in the hospital during follow-up with
a median time to death of 66 days after index. The remainder
of patients were censored with mean follow-up of 16032
days.
Table 2 shows the 30, 60, 90, and 180-day CIF estimates
of all bleeds and major bleeds stratiﬁed by the HAS-BLED
scores with the corresponding CIF plots in Figure. The
incidence of bleeding events increased with increasing HASBLED scores with statistically signiﬁcant differences between
HAS-BLED scores (P<0.001). Directly comparing the HASBLED scores of 3 and 4, which have been investigated
previously as cut points for distinguishing high risk, at 180days a score of 4 had cumulative incidence for major bleeding
of 3.1% (2.7–3.6%) and all bleeding of 7.3% (6.6–8.0%). A HASBLED score of 3 was associated with a cumulative incidence
of 5.3% (4.9–5.6%), which was signiﬁcantly lower than the
HAS-BLED ≥4 group (P<0.001). The cancer cohort had a
higher risk of bleeding than the overall and non-cancer cohort
and there was a consistent correlation between increases in
HAS-BLED scores and the risk of bleeding events.

Downloaded from http://ahajournals.org by on December 6, 2018

Figure. Cumulative incidence function plots of major (A through C) and all (D through F) bleeding events stratiﬁed by HAS-BLED scores for
overall (A and D), non-cancer (B and E), and cancer groups (C and F). HAS-BLED indicates Hypertension, Abnormal renal/liver function,
Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use. Graph lablel of HAS-BLED score of “4” indicates
HAS-BLED ≥ 4.
DOI: 10.1161/JAHA.117.007901
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ratios are presented incrementally (ie, comparing the level
with the previous level, rather than having a common
reference group). Anticoagulant treatment was included as a
covariate to control for any selection bias in treatment
selection. C-indices, a metric of model concordance or, the
ability of the model to identify those who will have outcomes,
are reported.
All data analysis was performed using SAS Enterprise
Guide (SAS Institute, Cary, NC) version 7.1 with an a priori
alpha of 0.05 for statistical signiﬁcance.
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Cox PH
HAS-BLED Score
Comparison

Competing Risks

csHR

95% CI

sdHR

95% CI

HAS-BLED 1 vs 0

1.34

1.15 to 1.56

1.34

1.15 to 1.55

HAS-BLED 2 vs 1

1.31

1.16 to 1.49

1.31

1.16 to 1.48

HAS-BLED 3 vs 2

1.22

1.06 to 1.39

1.21

1.06 to 1.39

HAS-BLED ≥4 vs 3

1.71

1.44 to 2.04

1.71

1.44 to 2.03

(A) Major bleeds, overall

(B) Major bleeds, no cancer
HAS-BLED 1 vs 0

1.44

1.20 to 1.73

1.44

1.20 to 1.72

HAS-BLED 2 vs 1

1.26

1.08 to 1.47

1.26

1.08 to 1.47

HAS-BLED 3 vs 2

1.37

1.16 to 1.63

1.37

1.15 to 1.63

HAS-BLED ≥4 vs 3

1.72

1.38 to 2.14

1.71

1.38 to 2.14

(C) Major bleeds, cancer only

20% to 30%. In the cancer only cohort, increases from 0
points to 3 points were not statistically signiﬁcant. For cancer,
only increasing from 3 points to 4 points total was signiﬁcant.
In Table 4, most of the HAS-BLED’s individual components
were signiﬁcant predictors of major and all bleeding with
hazard ratios ranging from 1.35 to 1.90. Age and high bleed
risk medication use were not found to be signiﬁcantly
predictive in these results.
Adding cancer to the model as an independent covariate
provided the strongest association of all included covariates,
with hazard ratios of 2.25 (95% CI: 1.98–2.56) in the causespeciﬁc model for major bleeds and 2.11 (95% CI: 1.85–2.41)
in the sub-distribution model for major bleeds. Similar results
were observed for all bleeds, with hazard ratios of 2.07 (95%
CI: 1.91–2.25) in the cause-speciﬁc model and 1.94 (95% CI:
1.78–2.11) in the sub-distribution model. C-indices ranged
between 0.66 to 0.73 and were highest for the non-cancer
cohort versus the cancer cohort.

HAS-BLED 1 vs 0

0.88

0.67 to 1.14

0.89

0.68 to 1.15

HAS-BLED 2 vs 1

1.22

0.99 to 1.49

1.23

1.00 to 1.50

Discussion

HAS-BLED 3 vs 2

0.95

0.77 to 1.19

0.95

0.77 to 1.19

HAS-BLED ≥4 vs 3

1.66

1.26 to 2.20

1.66

1.25 to 2.19

HAS-BLED 1 vs 0

1.29

1.18 to 1.41

1.28

1.17 to 1.41

HAS-BLED 2 vs 1

1.24

1.15 to 1.33

1.24

1.14 to 1.33

HAS-BLED 3 vs 2

1.24

1.14 to 1.35

1.24

1.14 to 1.35

HAS-BLED ≥4 vs 3

1.55

1.38 to 1.73

1.54

1.38 to 1.73

HAS-BLED 1 vs 0

1.35

1.21 to 1.50

1.34

1.21 to 1.50

HAS-BLED 2 vs 1

1.24

1.13 to 1.36

1.24

1.13 to 1.36

HAS-BLED 3 vs 2

1.33

1.20 to 1.48

1.33

1.20 to 1.48

HAS-BLED ≥4 vs 3

1.62

1.41 to 1.86

1.61

1.40 to 1.86

To our knowledge this is the largest and most comprehensive
analysis using the HAS-BLED score to assess bleeding in
patients with VTE. Our principal ﬁndings are that the HASBLED score has good predictive validity for bleeding risks in
patients with VTE, where a HAS-BLED score of ≥4 indicated a
clear delineation for those at high risk for major bleeding
among the total cohort. This observation remained consistent
when comparing risk for major bleeding among cancer and
non-cancer patients. Second, the addition of cancer as an
independent risk factor to bleeding risk merits consideration,
possibly as part of the B criterion (“bleeding tendency or
predisposition”) of the HAS-BLED score.
The use of the HAS-BLED score, or any risk stratiﬁcation tool,
in patients with VTE should be appropriately applied and not
misused.14 A designation of “high risk” in this population should
be used to “ﬂag up” high risk patients for additional review and
follow-up. More importantly, the management of reversible
bleeding risk factors (and the HAS-BLED score contains most of
the more common modiﬁable bleeding risk factors) should be
performed in all patients, and the designation of high bleed risk
is not intended for the withholding of anticoagulation therapy in
many patients with VTE.
The HAS-BLED score has been most validated in patients
with AF, where it was predictive of bleeding in patients on no
antithrombotic therapy, aspirin and anticoagulants (whether
warfarin or non-warfarin anticoagulants).4,15 Data in VTE
patients are more limited. For example, Kooiman, et al found
an increased risk of major bleeding at a HAS-BLED score of
≥3 in a cohort of 537 acute VTE patients.6 The present study
greatly extends the work by Kooiman et al by replicating the
study design using a substantially larger cohort, where

(D) All bleeds, overall
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(E) All bleeds, no cancer

(F) All bleeds, cancer only
HAS-BLED 1 vs 0

0.89

0.76 to 1.05

0.90

0.76 to 1.06

HAS-BLED 2 vs 1

1.07

0.94 to 1.22

1.08

0.95 to 1.23

HAS-BLED 3 vs 2

1.05

0.92 to 1.21

1.05

0.92 to 1.21

HAS-BLED ≥4 vs 3

1.41

1.17 to 1.69

1.40

1.17 to 1.69

C-indices (95% CI) for Cox PH and competing risks models, respectively: A=0.710 (0.698
–0.723), 0.700 (0.690–0.710); B=0.730 (0.712–0.748), 0.720 (0.710–0.730); C=0.685
(0.665–0.705), 0.670 (0.658–0.682); D=0.725 (0.715–0.735), 0.715 (0.705–0.725);
E=0.735 (0.728–0.742), 0.730 (0.720–0.740); F=0.670 (0.650–0.690), 0.660 (0.635–
0.685). CI indicates conﬁdence interval; csHR, cause-speciﬁc hazard ratio; HAS-BLED,
Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International
Normalized Ratio (INR), Elderly, Drugs or alcohol use; PH, proportional hazards; sdHR,
sub-distribution hazard ratio.

The results of the regression analyses are provided in
Table 3 for the HAS-BLED score and Table 4 for individual
components and cancer variables. Overall, an increase of 1
point in the HAS-BLED score increased the rate of bleeding by
DOI: 10.1161/JAHA.117.007901
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Table 3. Survival Regression Model Showing the Incremental
Cause-Speciﬁc and Sub-Distribution Hazard Ratios Comparing
HAS-BLED Scores Risk of Bleeding Events
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Table 4. Survival Regression Model Results Showing Individual HAS-BLED Components and Cancer Variables
Major Bleeds

All Bleeds

Cox PH (c-Index=0.722)

Competing Risks (c-Index=0.690)

Cox PH (c-Index=0.710)

Competing Risks (c-Index=0.685)

Variable

csHR

95% CI

sdHR

95% CI

csHR

95% CI

sdHR

95% CI

Age 65 to 74 vs ≤64, y

0.93

0.81 to 1.07

0.94

0.82 to 1.08

0.88

0.81 to 0.97

0.89

0.82 to 0.98

Age 75+ vs ≤64, y

0.87

0.78 to 0.98

0.88

0.79 to 0.99

0.85

0.79 to 0.91

0.85

0.80 to 0.92

Hypertension

1.35

1.22 to 1.50

1.35

1.21 to 1.49

1.29

1.21 to 1.37

1.28

1.21 to 1.37

Renal disease

1.55

1.36 to 1.76

1.54

1.35 to 1.75

1.59

1.46 to 1.72

1.58

1.45 to 1.71

Liver disease

1.40

1.20 to 1.62

1.38

1.19 to 1.60

1.43

1.31 to 1.57

1.41

1.29 to 1.55

Prior stroke

1.87

1.66 to 2.10

1.86

1.65 to 2.09

1.47

1.36 to 1.59

1.46

1.36 to 1.58

Prior bleeding

1.69

1.51 to 1.88

1.69

1.51 to 1.88

1.91

1.78 to 2.04

1.91

1.78 to 2.04

High risk medication use

0.92

0.83 to 1.02

0.92

0.84 to 1.02

0.97

0.92 to 1.04

0.98

0.92 to 1.04

Alcohol/drug abuse

1.55

1.16 to 2.08

1.55

1.16 to 2.07

1.59

1.33 to 1.90

1.58

1.32 to 1.89

Cancer

2.25

1.98 to 2.56

2.11

1.85 to 2.41

2.07

1.91 to 2.25

1.94

1.78 to 2.11

CI indicates conﬁdence interval; csHR, cause-speciﬁc hazard ratio; HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR),
Elderly, Drugs or alcohol use; PH, proportional hazards; sdHR, sub-distribution hazard ratio.
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estimates could be stabilized and individual elements of the
risk score could be examined.
The implications of these ﬁndings are that the current
designation of “high risk” for major bleeds may perhaps be
better attributed to those VTE patients with a HAS-BLED score
≥4 as Kooiman, et al postulated.6 As mentioned above, we
should not focus on designating a cut point for what is high risk,
but to provide further evidence for continued review or for
follow up and action to reduce the elements of the HAS-BLED
score that are modiﬁable (eg, alcohol excess, concomitant
NSAIDs or antiplatelets, uncontrolled hypertension, etc).14 In
the current analysis, utilizing a high-risk cut-off of HAS-BLED ≥4
would have a sensitivity of <5% for identifying true positive
cases given the distribution of the HAS-BLED scores in the
cohort studied (5% of patients had a HAS-BLED ≥4). Thus, to
prevent the most bleed events in a patient population, the range
of HAS-BLED scores should be considered, and modiﬁable risk
factors considered, for clinical intervention.
Cancer was included as a means to stratify the cohort
given the possible difference in baseline hazard for the cancer
population and also included as a covariate in the regression
models. Cancer is among the strongest risk factors for
VTE,16,17 and was present in roughly 20% of the cohort
studied. When included as an individual covariate along with
components of the HAS-BLED score, cancer was the strongest
predictor of major and overall bleeding. In the cancer cohort,
the HAS-BLED score without consideration of cancer
appeared to be less predictive of bleeding events compared
with the non-cancer cohort (Table 3). Along with the ﬁnding
that age and medication use were not strong predictors, a
bleeding risk score speciﬁcally tailored to a cancer population
with VTE as risk factors could inherently be different
DOI: 10.1161/JAHA.117.007901

compared with an AF population or a general VTE patient
group. Alternatively, cancer could be added as an additional
risk factor in a modiﬁed HAS-BLED score speciﬁc for patients
with VTE, where it could be part of the B criterion (“bleeding
tendency or predisposition”) of the HAS-BLED score. Further
work is needed to evaluate cancer as a risk factor for bleeding,
its suitability in a modiﬁed HAS-BLED score, and the
development of other risk scores speciﬁcally for the VTE
patient population. Of note, cancer has been included as an
independent risk factor in a recently developed, VTE-speciﬁc
bleed risk stratiﬁcation score, VTE-BLEED.18
Validating an existing risk stratiﬁcation tool like HAS-BLED
across multiple indications may help improve clinical adoption
and encourage its uptake in practice.19 Some urge caution in
applying bleeding risk scores in the clinical environment, due
to the development of these scores based on initial clinical
decisions to prescribe anticoagulants which necessitated that
the patients were considered lower bleed risk.20 Additionally,
bleed risk scores have only been modestly predictive of
bleeding in anticoagulated patients with VTE in a prior
validation study.21 Also, there is the perception that bleeding
risk scores are inappropriately used to deny patients anticoagulation because of their perceived “high risk” although
bleeding risk is highly dynamic and modiﬁable, and the
reversible risk factors for bleeding should be addressed in all
patients rather than just those at high risk.14 HAS-BLED has
been used widely in clinical and research settings,20 and
performs better than other bleeding risk scores (including
ATRIA).19 HAS-BLED should be compared with other bleed
scores speciﬁcally developed in the VTE population18 to
determine the comparative predictive validity of these similar
clinical tools.
Journal of the American Heart Association
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There are several limitations within this study. First, administrative claims data may not reliably capture all diagnoses
and procedures within the patient population.22 Second,
previous examination of cumulative incidence in HAS-BLED
scoring of major bleed risk have not incorporated the death as
a competing risk in the cohort, which suggests that our
analysis results may not be directly comparable to previous
studies. Our measure of death included only in-hospital death
as death data are not readily available in the MarketScan
data. This will have caused an underestimation of the number
of major bleeding events detected in this study and some
misclassiﬁcation of follow-up status as censored rather than
the competing risk of death. Misclassiﬁcation of death is
unlikely to have impacted the magnitude of effect between
the HAS-BLED score categories given how few (2%) patients
died during follow-up. Misclassifying death would have
underestimated the effect size between higher HAS-BLED
scores versus lower scores as the lower scores likely have a
smaller proportion of in-hospital deaths and, thus, an
overestimated cumulative incidence of bleeding.11,23 Further,
there were no clear differences between Cox and competing
risks regression models which suggested little effect of
missing death data. Lastly, the database primarily contains
patients with employer-sponsored health insurance plans,
which means that lower income patients, who tend to have
worse health outcomes, are likely under-represented.
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